Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) and Pioglitazone (PIO) Over 52 Weeks

被引：0
|
作者：
Forst, Thomas
Guthrie, Robert
Goldenberg, Ronald
Yee, Jacqueline
Vijapurkar, Ujjwala
Meininger, Gary
Stein, Peter
机构：
来源：
DIABETES | 2013年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1098-P
引用
收藏
页码：A284 / A284
页数：1
相关论文
共 50 条
  • [21] Canagliflozin (CANA) Reduces Serum Uric Acid (SUA) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Davies, Michael
    Trujillo, Angelina
    Vijapurkar, Ujjwala
    Damara-Ju, C. V.
    Meininger, Gary
    [J]. DIABETES, 2014, 63 : A283 - A284
  • [22] Consistent Effects of Canagliflozin (CANA) Across Racial Subgroups of Patients with Type 2 Diabetes Mellitus (T2DM)
    Gavin, James R., III
    Davies, Melanie J.
    Davies, Michael
    Vija-Purkar, Ujjwala
    Alba, Maria
    [J]. DIABETES, 2014, 63 : A285 - A285
  • [23] Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
    Yale, J. -F.
    Bakris, G.
    Cariou, B.
    Nieto, J.
    David-Neto, E.
    Yue, D.
    Wajs, E.
    Figueroa, K.
    Jiang, J.
    Law, G.
    Usiskin, K.
    Meininger, G.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (10): : 1016 - 1027
  • [24] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
    Neslusan, C.
    Teschemaker, A.
    Martin, S.
    Willis, M.
    Johansen, P.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [25] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM
    Schroeder, M.
    Johansen, P.
    Thompson, G.
    Willis, M.
    Neslusan, C.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A344 - A344
  • [26] Effects of Canagliflozin (CANA) on Biomarkers of Cardiovascular (CV) Stress in Older Patients with Type 2 Diabetes Mellitus (T2DM)
    Januzzi, James L.
    Butler, Javed
    Jarolim, Petr
    Sattar, Naveed
    Vijapurkar, Ujjwala
    Merton, Katherine W.
    Ren, Jimmy
    Canovatchel, William
    Desai, Mehul
    Davies, Michael J.
    [J]. DIABETES, 2017, 66 : LB40 - LB40
  • [27] Pioglitazone (PIO) enhances insulin sensitivity (IS) in patients with type 2 diabetes (T2DM)
    Johns, D
    Herz, M
    Tan, MH
    Robertson, KE
    Gonzalez, B
    Reviriego, J
    Grossman, LD
    [J]. DIABETES, 2002, 51 : A102 - A102
  • [28] Ramate as add-on to metformin (MET) in obese subjects with type 2 diabetes (T2DM)
    Toplak, H
    Vercruysse, F
    Sun, X
    Fitchet, M
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S159 - S159
  • [29] Target Achievement and Quality Measure (QM) Attainment with Titrated Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) as Add-on to Metformin (MET) plus Sitagliptin (SITA)
    Seufert, Jochen
    Aggarwal, Naresh
    Bailey, Robert
    Cao, Anjun
    Fung, Albert
    Pfeifer, Michael
    Alba, Maria
    Rodbard, Helena W.
    [J]. DIABETES, 2016, 65 : A308 - A308
  • [30] Efficacy and safety of canagliflozin (CANA) in patients with type 2 diabetes mellitus (T2DM) who progressed to stage 3A chronic kidney disease during treatment
    Roussel, R.
    de Zeeuw, D.
    Law, G.
    Meininger, G.
    [J]. DIABETOLOGIA, 2014, 57 : S322 - S323
12345